• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rhinovirus Infection - Pipeline Review, H2 2012 Product Image

Rhinovirus Infection - Pipeline Review, H2 2012

  • ID: 2366267
  • December 2012
  • 40 pages
  • Global Markets Direct

Rhinovirus Infection – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Rhinovirus Infection - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection. Rhinovirus Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rhinovirus Infection.
- A review of the Rhinovirus Infection products under development by companies and universities/research READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Rhinovirus Infection Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Rhinovirus Infection 7
Rhinovirus Infection Therapeutics under Development by Companies 9
Rhinovirus Infection Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Rhinovirus Infection Therapeutics – Products under Development by Companies 14
Rhinovirus Infection Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Rhinovirus Infection Therapeutics Development 16
Discovery Laboratories, Inc. 16
Clarassance, Inc. 17
Rhinovirus Infection – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
lucinactant - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
lucinactant LS - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dexamethasone beloxil - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Rhinovirus Infection Therapeutics – Drug Profile Updates 29
Rhinovirus Infection Therapeutics - Dormant Products 32
Rhinovirus Infection – Product Development Milestones 33
Featured News & Press Releases 33
May 05, 2010: Discovery Lab's Surfaxin LS Improves Pulmonary Function And Reduces Lung Inflammation In Established Model Of RDS 33
May 05, 2009: Discovery Labs’ Surfaxin Significantly Improves Lung Surfactant Distribution In Preclinical RDS Model 34
May 31, 2007: Discovery Laboratories, Inc Announced Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published In Pediatrics 35
May 18, 2005: Discovery Laboratories, Inc Announced New Data of Surfaxin Survival Benefit Continues Through One Year Of Life 35
Feb 14, 2005: Discovery Labs Receives Approvable Letter From FDA For Surfaxin For Respiratory Distress Syndrome In Premature Infants 36
Feb 02, 2005: INO Therapeutics Entered Into Agreement With Forest Laboratories To Co-Promote Infasurf 37
Sep 14, 1998: Forest Laboratories Infasurf Found To Infringe Abbott's Survantas Patents 37
Jul 17, 1995: Forest Laboratories Announced FDA Response To Infasurf Meeting 38
May 17, 1995: Forest Laboratories Announced FDA Action On Infasurf 38
Mar 14, 1995: Forest Laboratories Submittted New Drug Application For Infasurf For The Treatment Of Respiratory Distress Syndrome 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Rhinovirus Infection, H2 2012 7
Products under Development for Rhinovirus Infection – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Discovery Laboratories, Inc., H2 2012 16
Clarassance, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Rhinovirus Infection Therapeutics – Drug Profile Updates 29
Rhinovirus Infection Therapeutics – Dormant Products 32

List of Figures
Number of Products under Development for Rhinovirus Infection, H2 2012 7
Products under Development for Rhinovirus Infection – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos